Levetiracetam Versus Phenobarbital for Neonatal Seizures: A Randomized Controlled Trial
- 8 May 2020
- journal article
- research article
- Published by American Academy of Pediatrics (AAP) in PEDIATRICS
- Vol. 145 (6)
- https://doi.org/10.1542/peds.2019-3182
Abstract
BACKGROUND AND OBJECTIVES: There are no US Food and Drug Administration–approved therapies for neonatal seizures. Phenobarbital and phenytoin frequently fail to control seizures. There are concerns about the safety of seizure medications in the developing brain. Levetiracetam has proven efficacy and an excellent safety profile in older patients; therefore, there is great interest in its use in neonates. However, randomized studies have not been performed. Our objectives were to study the efficacy and safety of levetiracetam compared with phenobarbital as a first-line treatment of neonatal seizures. METHODS: The study was a multicenter, randomized, blinded, controlled, phase IIb trial investigating the efficacy and safety of levetiracetam compared with phenobarbital as a first-line treatment for neonatal seizures of any cause. The primary outcome measure was complete seizure freedom for 24 hours, assessed by independent review of the EEGs by 2 neurophysiologists. RESULTS: Eighty percent of patients (24 of 30) randomly assigned to phenobarbital remained seizure free for 24 hours, compared with 28% of patients (15 of 53) randomly assigned to levetiracetam (P < .001; relative risk 0.35 [95% confidence interval: 0.22–0.56]; modified intention-to-treat population). A 7.5% improvement in efficacy was achieved with a dose escalation of levetiracetam from 40 to 60 mg/kg. More adverse effects were seen in subjects randomly assigned to phenobarbital (not statistically significant). CONCLUSIONS: In this phase IIb study, phenobarbital was more effective than levetiracetam for the treatment of neonatal seizures. Higher rates of adverse effects were seen with phenobarbital treatment. Higher-dose studies of levetiracetam are warranted, and definitive studies with long-term outcome measures are needed.Keywords
This publication has 50 references indexed in Scilit:
- Effects of Neonatal Antiepileptic Drug Exposure on Cognitive, Emotional, and Motor Function in Adult RatsThe Journal of pharmacology and experimental therapeutics, 2011
- Pattern of antiepileptic drug-induced cell death in limbic regions of the neonatal rat brainEpilepsia, 2011
- Electrographic Seizures During Therapeutic Hypothermia for Neonatal Hypoxic-Ischemic EncephalopathyJournal of Child Neurology, 2011
- Interobserver Reproducibility of Electroencephalogram Interpretation in Critically Ill ChildrenJournal of Clinical Neurophysiology, 2011
- Clinical Neonatal Seizures are Independently Associated with Outcome in Infants at Risk for Hypoxic-Ischemic Brain InjuryThe Journal of Pediatrics, 2009
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2008
- Antiepileptic Drug-Induced Neuronal Cell Death in the Immature Brain: Effects of Carbamazepine, Topiramate, and Levetiracetam as Monotherapy versus PolytherapyThe Journal of pharmacology and experimental therapeutics, 2007
- Sulthiame but not levetiracetam exerts neurotoxic effect in the developing rat brainExperimental Neurology, 2005
- Postneonatal epilepsy following amplitude-integrated EEG-detected neonatal seizuresPediatric Neurology, 2005
- Side effects of phenobarbital in toddlers; behavioral and cognitive aspectsThe Journal of Pediatrics, 1979